BET bromodomain proteins Brd2, Brd3 and Brd4 selectively regulate metabolic pathways in the pancreatic β-cell. Rattus norvegicus

Displacement of Bromodomain and Extra-Terminal (BET) proteins from chromatin has promise for cancer and inflammatory disease treatments, but roles of BET proteins in metabolic disease remain unexplored. Small molecule BET inhibitors, such as JQ1, block BET protein binding to acetylated lysines, but lack selectivity within the BET family (Brd2, Brd3, Brd4, Brdt), making it difficult to disentangle contributions of each family member to transcriptional and cellular outcomes. Here, we demonstrate multiple improvements in pancreatic β-cells upon BET inhibition with JQ1 or BET-specific siRNAs. JQ1 (50-400 nM) increases insulin secretion from INS-1 cells in a concentration dependent manner. JQ1 increases insulin content in INS-1 cells, accounting for increased secretion, in both rat and human islets. Higher concentrations of JQ1 decrease intracellular triglyceride stores in INS-1 cells, a result of increased fatty acid oxidation. Specific inhibition of both Brd2 and Brd4 enhances insulin transcription, leading to increased insulin content. Inhibition of Brd2 alone increases fatty acid oxidation. Overlapping yet discrete roles for individual BET proteins in metabolic regulation suggest new isoform-selective BET inhibitors may be useful to treat insulin resistant/diabetic patients. Results imply that cancer and diseases of chronic inflammation or disordered metabolism are related through shared chromatin regulatory mechanisms. Overall design: BET proteins are not redundant in their functions, thus pan-BET inhibitors like JQ1 cannot properly be interpreted without specific RNA knockdown or small molecules of proven selectivity. Here, we expose INS-1 cells, a rat insulinoma model for the pancreatic beta cell, to selective siRNAs to ablate Brd2, Brd3 or Brd4 mRNAs and compared genome-wide changes in transcription to non-targeted siRNA control. As expected, three resolvably different patterns of gene expression were identified, establishing that each BET protein controls its own set of target genes.

溴结构域与额外末端（Bromodomain and Extra-Terminal, BET）蛋白从染色质上的解离在癌症与炎症性疾病治疗中颇具潜力，但BET蛋白在代谢疾病中的功能尚未得到阐明。小分子BET抑制剂（如JQ1）可阻断BET蛋白与乙酰化赖氨酸的结合，但该类药物在BET家族（包含Brd2、Brd3、Brd4、Brdt）内缺乏亚型选择性，这使得厘清每个家族成员对转录及细胞结局的贡献变得极为困难。本研究证实，使用JQ1或BET特异性小干扰RNA（siRNA）抑制BET蛋白，可对胰腺β细胞产生多重改善效果。JQ1（50-400 nM）以浓度依赖性方式提升INS-1细胞的胰岛素分泌水平；JQ1可增加INS-1细胞以及大鼠和人类胰岛的胰岛素含量，这正是其分泌水平提升的原因。更高浓度的JQ1则会降低INS-1细胞内的甘油三酯储存量，该现象源于脂肪酸氧化的增强。同时抑制Brd2与Brd4可增强胰岛素转录，进而提升胰岛素含量；单独抑制Brd2则可促进脂肪酸氧化。各BET蛋白在代谢调控中存在重叠又各具特异性的功能，这提示新型亚型选择性BET抑制剂或可用于治疗胰岛素抵抗/糖尿病患者。研究结果表明，癌症、慢性炎症性疾病与代谢紊乱疾病或可通过共享的染色质调控机制相互关联。实验设计概述：BET蛋白的功能并不冗余，因此若缺乏特异性RNA敲低工具或经验证具有选择性的小分子化合物，便无法准确解读JQ1这类泛BET抑制剂的作用效果。本研究将大鼠胰岛素瘤胰腺β细胞模型INS-1细胞暴露于靶向敲除Brd2、Brd3或Brd4 mRNA的特异性siRNA中，并将全基因组转录组变化与非靶向siRNA对照组进行比较。正如预期，研究鉴定出三种可明确区分的基因表达模式，证实每个BET蛋白均调控一套独特的靶基因。